OTHER · Unmapped registry intervention
Laboratory Biomarker Analysis
Find medicine records ·
Find other trials using this name
Clinical trial
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
NCT02282345
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Talazoparib
Normalized identity: talazoparibView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedTalazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Deleterious BRCA1 Gene Mutationunresolved
Deleterious BRCA2 Gene Mutationunresolved
HER2/Neu Negativeunresolved
Interventions
TalazoparibDRUG · verified · RxNorm: talazoparib
Sponsors & collaborators
M.D. Anderson Cancer Centerlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02282345 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.